122 related articles for article (PubMed ID: 11441287)
21. Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies.
Gabriel DA; Shea TC; Serody JS; Moore DT; Kirby SL; Harvey D; Krasnov C
Biol Blood Marrow Transplant; 2005 Dec; 11(12):1022-30. PubMed ID: 16338625
[TBL] [Abstract][Full Text] [Related]
22. The effect of cytoprotective agents in platinum anticancer therapy.
Jakupec MA; Galanski M; Keppler BK
Met Ions Biol Syst; 2004; 42():179-208. PubMed ID: 15206103
[No Abstract] [Full Text] [Related]
23. [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
Büntzel J; Glatzel M; Schuth J; Weinaug R; Küttner K; Fröhlich D
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():37-40. PubMed ID: 10584140
[TBL] [Abstract][Full Text] [Related]
24. Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?
Peters K; Mücke R; Hamann D; Ziegler PG; Fietkau R
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():23-6. PubMed ID: 10584136
[TBL] [Abstract][Full Text] [Related]
25. Advances in supportive therapy.
Facchini T
Zentralbl Gynakol; 1996; 118(10):589-90. PubMed ID: 8912478
[No Abstract] [Full Text] [Related]
26. Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha.
Koukourakis MI; Giatromanolaki A; Chong W; Simopoulos C; Polychronidis A; Sivridis E; Harris AL
Cancer Chemother Pharmacol; 2004 Jan; 53(1):8-14. PubMed ID: 14574457
[TBL] [Abstract][Full Text] [Related]
27. [Amifostine: current and future applications in cytoprotection].
Lenoble M
Bull Cancer; 1996 Sep; 83(9):773-87. PubMed ID: 8952658
[TBL] [Abstract][Full Text] [Related]
28. Re: Sodium thiosulfate in cisplatin overdose by Erdlenbruch B et al., Med Pediatr Oncol 2002;38:349-352.
Bleyer A; Alberts DS
Med Pediatr Oncol; 2003 Jun; 40(6):413; author reply 414. PubMed ID: 12692822
[No Abstract] [Full Text] [Related]
29. Current variations in childhood cancer supportive care in the Netherlands.
Loeffen EA; Mulder RL; van de Wetering MD; Font-Gonzalez A; Abbink FC; Ball LM; Loeffen JL; Michiels EM; Segers H; Kremer LC; Tissing WJ
Cancer; 2016 Feb; 122(4):642-50. PubMed ID: 26588808
[TBL] [Abstract][Full Text] [Related]
30. Potential for use of amifostine in cervical cancer.
Small W
Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241
[TBL] [Abstract][Full Text] [Related]
31. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Capizzi RL
Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
[TBL] [Abstract][Full Text] [Related]
32. Cytoprotective agents used in the treatment of patients with cancer.
Hogle WP
Semin Oncol Nurs; 2007 Aug; 23(3):213-24. PubMed ID: 17693348
[TBL] [Abstract][Full Text] [Related]
33. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
34. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine.
Mehta MP
Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):14-6. PubMed ID: 9794996
[TBL] [Abstract][Full Text] [Related]
35. Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):1-2. PubMed ID: 10348254
[No Abstract] [Full Text] [Related]
36. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
37. Amifostine in the management of radiation-induced and chemo-induced mucositis.
Bensadoun RJ; Schubert MM; Lalla RV; Keefe D
Support Care Cancer; 2006 Jun; 14(6):566-72. PubMed ID: 16586122
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
[TBL] [Abstract][Full Text] [Related]
39. Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy.
Koukourakis MI; Abatzoglou I; Sivridis L; Tsarkatsi M; Delidou H
Anticancer Res; 2006; 26(3B):2437-43. PubMed ID: 16821629
[TBL] [Abstract][Full Text] [Related]
40. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine.
Castiglione F; Dalla Mola A; Porcile G
Tumori; 1999; 85(2):85-91. PubMed ID: 10363072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
